LYNTERO 150MG TAB
Prescription Required
Sale price
₹ 5,000.00
Regular price
MRP: ₹ 8,447.00
41% OFF
Inclusive of all taxes.
Couldn't load pickup availability
LYNTERO 150MG TAB
Regular price
₹ 5,000.00
Regular price
₹ 8,447.00
Sale price
₹ 5,000.00
(-41%)
Unit price
per
LYNTERO 150MG TAB
Sale price
₹ 5,000.00
Regular price
MRP: ₹ 8,447.00
41% OFF
- Introduction
- Uses
- Storage
- Safety
- Side effects
- Abouts RareMeds
- Disclaimer
Introduction
Lyntero 150mg Tablet contains abemaciclib, a CDK4/6 inhibitor that slows the growth of hormone receptor-positive breast cancer cells.
Uses
Lyntero 150mg Tablet is used in combination with endocrine therapy for advanced breast cancer.
- Hormone receptor-positive breast cancer
- HER2-negative advanced breast cancer
- Metastatic breast cancer
Storage
- Store below 30°C in a cool, dry place.
- Keep away from moisture.
Safety Information
- Monitor blood counts and liver function regularly.
- Report diarrhoea or signs of infection promptly.
Possible Side Effects
Possible side effects may include:
- Diarrhoea
- Fatigue
- Nausea
- Low white blood cell count
- Infections
- Elevated liver enzymes
About RareMeds
We, at RareMeds, make a diligent attempt to deliver accurate, expert-drafted and thoroughly reviewed medicine-related information to our consumers. However, it should, by no means, be considered a substitute for a prescription from a certified doctor or a trustworthy doctor-patient relationship. In fact, we detest any form of self-medication without expert advice.
The sole purpose of the information on our portal is to educate our consumers, which helps improve communication between a doctor and a patient. The information is by no means complete in its entirety and should not be used to diagnose or treat any medical condition.
No amount of information can replace the experience and expertise of a doctor; therefore, his/her advice always holds priority and should be followed appropriately.
Disclaimer
Lyntero is a prescription targeted anticancer medicine.
It should only be used under the supervision of a qualified oncologist.